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Abstract
The development of an autologous tissue engineered vascular graft (TEVG) holds
great promise for improving outcomes in congenital heart surgery. The first clinical trial
showed that this approach is safe and effective but that the primary mode of failure is
stenosis. In a C57BL/6 mouse model of unseeded TEVGs implanted as inferior vena cava
interposition grafts, neovessels form in 2 weeks and patent grafts show endothelial and
smooth muscle cell (SMC) layers, but occluded grafts show accumulation of SMCs. This
suggests stenosis results from abnormal SMC in-growth in the neointima. Studies on
fibrosis have shown that resident endothelial cells (EC) contribute to fibroblast
accumulation through endothelial-mesenchymal transition (EMT). We utilized transgenic
EC lineage-tracing mouse models to track the occurrence of EMT in our TEVG and
found an increased percentage of cells co-expressing LacZ and smooth muscle actin in
occluded grafts, suggesting that EMT contributes to occlusion in our TEVG. We
hypothesized that ECs in our TEVG undergo EMT driven by TGF-B to contribute to
stenosis. Immunohistochemistry and qRT-PCR showed higher expression of TGF-B in
occluded compared to patent grafts. In vivo expression of a soluble FGF trap virus to
increase TGF-B signaling and thus increase EMT was found to result in a significantly
increased stenosis rate in our TEVG. We next modulated this pathway by intraperitoneal
administration of a small molecule inhibitor of TGF-B receptor type 1 (SB431542).
Grafts from treated mice had significantly increased patency rates and internal diameters
at 2 weeks compared to controls while maintaining normal neovessel architecture. We
then designed a novel local delivery system for this TGF-B R1 inhibitor in our grafts and
showed that local drug delivery inhibits stenosis without cell seeding and maintains
normal neovessel formation. These results suggest that EMT under the control of TGF-B
is a significant mediator of stenosis and that modulation of this pathway by local drug
delivery might be useful in next generation TEVGs.
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Introduction
Clinical Background
Despite major advances in medical and surgical treatment, congenital heart
disease (CHD) remains the leading cause of death due to congenital anomalies in the
newborn period [1]. Single ventricle anomalies make up one of the largest groups of
cardiac anomalies resulting in life-threatening diseases. These include diseases such as
tricuspid atresia, pulmonary atresia, and hypoplastic left heart syndrome, in which only
one ventricle is of adequate functional size. These anomalies result in mixing of the
deoxygenated pulmonary circulation and the oxygenated systemic circulation, causing
chronic hypoxia and cyanosis. This mixed circulation can cause volume overload that can
lead to heart failure. Untreated single ventricle anomalies are associated with up to 70%
mortality during the first year of life [2]. The treatment of choice for this CHD is surgical
reconstruction, the goal of which is to separate the pulmonary circulation from the
systemic circulation, preventing cyanosis, volume overload, and heart failure [3, 4]. This
is accomplished through a series of staged procedures referred to as the modified Fontan
operation with extra cardiac total cavopulmonary connection (EC TCPC). This operation
has considerably improved long-term survival but is considered only a palliative
procedure with significant morbidity and mortality [3, 4].
An important cause of complications in EC TCPC is the conduit used to connect
the inferior vena cava (IVC) to the pulmonary artery [5]. Much of the late morbidity is
attributed to problems with conduit use [6] and while as many as 10,000 children undergo
such reconstructive cardiothoracic operations each year, it is widely accepted that the
ideal conduit has not yet been developed [7-9]. Data describing long-term graft failure
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rates for conduits used for EC TCPC is limited but long-term data for similar congenital
heart conduit operations suggest outcomes are poor [10]. Late problems include conduit
degeneration with progressive obstruction and susceptibility to infection. Synthetic
conduits lack growth potential, necessitating re-operation when a pediatric patient
outgrows the graft. Synthetic conduits are also a significant cause of thromboembolic
complication due to the area of synthetic material in contact with blood causing
activation of the coagulation cascade [11]. It is assumed that all such conduits eventually
need to be replaced. Re-operation is associated with significant morbidity and early postoperative mortality rates as high as 5% [10]. Long-term graft failure rates have been
reported at 70-100% at 10-15 years [12, 13]. The best results have been obtained when
autologous tissue was used for the conduit with long-term patency rates of over 80%
[14]. Autografts, conduits created from an individual’s own tissue, have better long-term
effectiveness than any synthetic or biological conduit currently available but these are
limited in supply, suggesting the need for an alternate approach [10, 13-15].

Tissue Engineering Approach
Tissue engineering offers a strategy for constructing autologous grafts and thereby
increasing the pool of potential autografts for use as conduits [16]. Using the classical
tissue-engineering paradigm, autologous cells can be seeded onto a biodegradable tubular
scaffold, which provides sites for cell attachment and space for neotissue formation [17].
As the neotissue forms, the scaffold degrades creating a purely biological graft. The
resulting neotissue can thus function as a vascular graft in cardiothoracic operations [18].
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Extensive large animal studies have demonstrated the feasibility of using tissueengineering methodology to construct conduits for use as large grafts [18-21].

Clinical Trial
Based on the success of animal studies, Shinoka performed a pilot clinical study
in Japan in 2001 to evaluate the feasibility and safety of using a tissue engineered
vascular graft (TEVG) as a conduit for EC TCPC in patients with single ventricle cardiac
anomalies [22-24]. Twenty-five TEVGs seeded with autologous bone marrow
mononuclear cells (BM-MNC) were implanted with follow-up out through seven years
[19, 25]. At the most recent follow-up, the tissue engineered vascular grafts were shown
to function well without evidence of graft failure. No graft had to be replaced and there
was no graft related mortality. An additional advantage of this technology is almost
eliminating the need for antiplatelet, antigoagulant, and immunosuppressive therapy. All
patients had both antiplatelet and anticoagulant medications discontinued by 6 months
postoperatively and 40% of patients remained free of any daily medications long term in
stark contrast to the lifetime need for anticoagulation with the use of synthetic grafts [22].
Long-term follow-up, however, revealed graft stenosis in 16% of patients (Table 1).
Stenosis in these patients was frequently asymptomatic and all were successfully treated
with angioplasty and stenting. In addition, serial imaging demonstrated the growth
potential of these grafts, an element that is extremely important in the pediatric
population (Figure 1). These data support the overall feasibility and safety of using
vascular tissue-engineering technology in the pediatric clinical setting [22].
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Table 1: Late term status after TEVG implantation in clinical trial
Patient

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Age at
Operation
(Years)
2
1
7
21
4
12
17
19
3
2
13
2
2
2
2
2
24
1
11
2
3
4
4
13
2

Patient
Status

Graft Status

Graft
Patency

Graft Related
Complications

alive
alive
alive
alive
alive
alive
alive
dead
alive
dead
alive
dead
alive
alive
alive
alive
alive
alive
alive
alive
alive
alive
alive
alive
dead

intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact
intact

patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent
patent

none
none
stenosis
none
none
none
none
none
stenosis
none
stenosis
none
thrombosis
none
none
none
none
stenosis
none
none
none
none
none
none
none

Table 1:
Late term status after TEVG implantation in clinical trial. Most
recent follow-up at mean of 5.8 years showed no graft-related mortality and no evidence
of aneurysm formation, graft rupture, or ectopic calcification. 4 out of 25 patents
developed asymptomatic stenosis that was picked up on routine serial imaging and were
successfully treated with angioplasty. All implanted TEVG are currently intact and
patent. (Adapted from Hibino (2010) [22]).
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Figure 1: Growth potential of TEVG in clinical trial

Figure 1:
Growth potential of TEVG in clinical trial. A. Magnetic resonance
image (MRI) 9 months following implantation of EC TCPC graft. B. 3-D computed
tomography angiogram (CTA) of graft one year after implantation. Red arrows indicate
location of tissue engineered vascular graft. (Adapted from Shinoka (2008) [26]).
Complications arising from the use of currently available synthetic vascular grafts
are a leading cause of morbidity and mortality after congenital heart surgery [5]. The lack
of growth potential of synthetic conduits is problematic. Use of over-sized grafts in an
attempt to avoid outgrowing a conduit is widely practiced, but graft over-sizing has an
increased risk of complications [27]. Delaying surgery to minimize re-operations can lead
to cardiac dysfunction or heart failure due to prolonged exposure to volume overload and
chronic hypoxia [11]. The development of a vascular graft with growth potential would
eliminate this problem. Review of the data suggest that the safety and efficacy of the use
of TEVGs in congenital heart surgery is excellent, but mechanisms underlying the
process of neovessel formation that lead to TEVG failure have remained incompletely

12
understood. Exploring these processes is essential to create an improved tissue
engineered vascular conduit. Also, as noted at long-term follow-up it was found that the
primary mode of failure for TEVG is stenosis [18-22, 25]. Identification of the mediators
of stenosis in TEVG and determination of the mechanisms underlying neovessel
formation would identify targets and potential strategies for preventing stenosis and
thereby enable the rational design of improved TEVG.

Mechanisms of Neotissue Formation
Neotissue Growth
In order to better study the mechanisms of TEVG formation and stenosis in vivo,
mouse models have been developed to recapitulate the results of the human trial (Figure
2). This approach includes a method for constructing sub-1mm tubular scaffolds similar
to the scaffold used in the clinical trial [28]. These scaffolds can be seeded with cells to
create TEVG. Use of immunodeficient SCID-beige mice has enabled transplantation of
human cells or cells from strains of transgenic mice without the need for
immunosuppression. This has proven to be an excellent model for evaluating TEVG [29,
30]. In an initial pilot study TEVG were implanted as infrarenal IVC interposition grafts
and observed over a six-month time course to determine the effect of human BM-MNC
seeding on neovessel formation. The seeded TEVG functioned well and had better longterm graft patency and less stenosis than the unseeded scaffolds [31]. Quantitative
morphometric analysis demonstrated that unseeded TEVG had significantly increased
wall thickness and luminal narrowing compared to seeded TEVG. Further analysis
revealed that the primary mode of failure is stenosis characterized by graft wall
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thickening and progressive luminal narrowing, which ultimately leads to luminal
obliteration and vessel occlusion by inward remodeling. Cell seeding appears to inhibit
inward remodeling and promote outward remodeling in neovessel formation [31].

Figure 2: TEVG in a mouse model

Figure 2:
TEVG in a mouse model. A. Gross image of PGA-P(CL/LA) TEVG
before surgical implantation. Scale bar: 1 mm. B. Intraoperative photograph of an inferior
vena cava (IVC) interposition graft in C57BL/6 mouse. C. Venous phase contrast CT of
occluded TEVG in CB17 mouse. D. Scanning electron microscope image of PGAP(CL/LA) TEVG. Scale bar: 500 μm. E. Hematoxylin and eosin (H&E) stain of TEVG
at day 7 and day 14. Scale bar: 200 μm.
A series of time course experiments using ovine and canine models demonstrated
the stepwise morphologic changes that occur when a seeded scaffold is implanted as a
vascular interposition graft [19-21, 32]. The process begins with a host-derived
inflammatory response followed by formation of a monolayer of endothelial cells lining
concentric layers of smooth muscle that develop on the luminal surface of the scaffold.
As the scaffold degrades, the cells produce an extracellular matrix rich in collagen,
elastin, and glycosaminoglycans, resulting in the formation of a neovessel with
biomechanical properties similar to native blood vessel complete with intimal, medial,
and adventitial layers that histologically resemble native vessel. The vascular neotissue
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shows evidence of normal growth and development including increase in size
proportional to the surrounding native tissue and expression of Ephrin B4, the molecular
determinant of veins, when implanted as an IVC graft [32].

Neotissue Remodeling
Extensive histological and immunohistochemical (IHC) characterization has been
performed to show the changes in TEVG over time in a murine model and these have
documented the natural history of neovessel formation, the process of developing from a
biodegradable tubular scaffold seeded with BM-MNC into a vascular conduit that
resembles and functions as a native blood vessel. Six-months after implantation, the
resulting neotissue possesses an internal monolayer of endothelial cells surrounded by
inner smooth muscle layers, and an organized extracellular matrix. Some groups have
hypothesized that stem cells within the bone marrow cell population differentiate into the
cells of the neotissue [33], but characterizing the human BM-MNC population, however,
revealed very few endothelial cells, smooth muscle cells and vascular progenitor cells
and therefore it seemed that the seeded cells were unlikely to be the ultimate source of the
vascular neotissue. This hypothesis is not consistent with classic tissue engineering
theory which views the seeded cells as building blocks of neotissue, but instead supports
a regenerative medicine paradigm in which the seeded scaffold is used to augment the
body’s own reparative mechanisms to “regenerate” missing tissue. To test this
hypothesis, species-specific IHC stains were used to determine the fate of the seeded
human BM-MNC in the mouse host. Results of these studies revealed that seeded cells
were replaced by host cells one to three-weeks after implantation. These findings were
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confirmed using human specific GAPDH RNA detection via qRT-PCR, confirming the
presence of human RNA on the TEVG prior to implantation followed by a dramatic
decrease such that no human RNA could be found by post-operative day 7 [31].
Based on these preliminary studies it has been hypothesized that seeded cells
exert their effect via a paracrine mechanism by releasing chemokines that recruit host
cells to the scaffold. These host cells are then critical for vascular neotissue formation
and promote outward remodeling to maintain graft patency. IHC characterization
demonstrated that the TEVG were initially infiltrated by host-derived monocytes and
macrophages. Based on quantitative IHC data a correlation was noted between degree of
early inflammatory response and graft patency. Specifically, the seeded grafts had
significantly more macrophages in the early period compared to unseeded vascular grafts,
suggesting that macrophage recruitment may be important in the process of promoting
outward remodeling during neovessel formation. IL-1B and MCP-1 were found to be
produced in abundant quantity. Studies of TEVG seeded with BM-MNC from MCP-1
knockout mice or wild-type implanted into a SCID-beige vascular interposition graft
model revealed that TEVG seeded with MCP-1 knockout BM-MNC developed
significantly more wall thickening and luminal narrowing, suggesting that MCP-1 plays a
critical role in inducing outward remodeling. Alginate microspheres were created and
incorporated into the wall of the scaffold to provide controlled release of MCP-1. A study
using this scaffold showed that an MCP-1 eluting scaffold can inhibit stenosis in the
absence of BM-MNC seeding. These studies suggest that BM-MNC seeded scaffolds
transform into functional vessels by means of an inflammation-mediated process of
vascular remodeling (Figure 3) [31].
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Figure 3: TEVG remodeling in a mouse model

Figure 3:
TEVG remodeling in a mouse model. A. Inflammation-mediated
process of graft remodeling. Seeded BM-MNC attach to the scaffold and release
cytokines. MCP-1 recruits host monocytes which infiltrate the scaffold and begin to
direct vascular neotissue formation, ultimately resulting in the formation of neovessels
composed of a concentric layers of smooth muscle cells recruited from the neighboring
native vessel wall embedded in an extracellular matrix with a monolayer of endothelial
cells lining the luminal surface. B. TEVG gross and microscopic morphology changes
over time and ultimately resembles the native IVC with a smooth muscle cell layer lined
by an endothelial cell layer as shown in gross images and hematoxylin and eosin stained
section slides. (Adapted from Roh (2010) [31]).
According to this model, the seeded BM-MNC attach to the scaffold and begin to
release MCP-1. Once implanted as an IVC interposition graft, MCP-1 recruits host
monocytes which infiltrate the scaffold and begin to direct or participate in vascular
neotissue formation, ultimately resulting in the formation of neovessels composed of
concentric layers of smooth muscle cells recruited from the neighboring native vessel
wall embedded in an extracellular matrix with a monolayer of endothelial cells lining the
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luminal surface [31]. Recent studies used composite grafts consisting of male vessel
segments implanted into female mice and wildtype mice given GFP bone marrow
transplants to determine the source of neotissue cells. These studies showed that the cells
of the neovessel do not derive from the bone marrow or the seeded cells but actually arise
as a result of migration from the adjacent vessel segment as an augmented regenerative
response [34].

Clinical Trial at Yale School of Medicine
It will be important to have a deeper understanding of the mechanisms of
neotissue formation and stenosis for an FDA approved clinical trial that has been initiated
at Yale School of Medicine to investigate the use of TEVG in pediatric patients [26, 35].
All elements of the process of TEVG development need to be considered in this context
including scaffold materials, cells for seeding grafts, seeding techniques, patient
selection, and imaging advances.

Scaffold Materials
Scaffold materials must be biodegradable and non-immunogenic. They must
provide space for cell attachment while allowing for appropriate structural integrity until
neotissue can form. Standard approaches involve the use of polymers of polyglycolic
acid (PGA), polylactic acid (PLA), and poly e-caprolactone (PCL) in varying
concentrations to meet the compliance specifications of the vascular system into which
the graft is being introduced [36, 37]. Electrospinning is a newer approach for creating
vascular graft scaffolds that can be made with finely tuned biomechanical specifications
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[38]. Other groups have pioneered the use of decellularized biologic materials including
human and porcine vessels [39]. Additional novel approaches involve the use of human
umbilical vein as a living scaffold and grafts made using sheets of a patient’s own
fibroblasts [40-42].

Cells for Seeding
Many cell types have been considered as possibilities for seeding vascular grafts
[43, 44]. Some groups have investigated the use of endothelial cells and smooth muscle
cells for seeding but these approaches require much longer incubation times, presenting
additional risk of contamination along with a slower process to make TEVGs ready for
implantation. Recent investigation has focused on shortening the time required for this
approach, including the use of novel flow chambers and other bioreactors [44].
Bone marrow mononuclear cells have been found to be useful for seeding as they
are readily available from patients by means of bone marrow aspiration and show the
most promise in inducing proper neotissue formation [45]. There are several different
approaches for purifying mononuclear cells from the bone marrow. The traditional
approach has involved Ficoll centrifugal separation based on cell mass, but this takes
several hours. A newer approach involves using a specially designed filter to separate
out cells of a particular size [46]. Alternative methods need to optimize speed and
specificity for the cells of interest, while maintaining sterility and cell viability.
Alternative cells that might allow for even more effective cell seeding could
include embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, a newer
autologous approach to developing pluripotent cells [47-49]. All pluripotent cells present
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the risk of teratoma formation and so more investigation is needed into the use of these
cell types for the seeding of TEVGs. It is yet to be seen whether an optimal approach
would involve seeding with undifferentiated ES or iPS cells or rather using these cells
derived from a patient to make a differentiated cell line of smooth muscle and/or
endothelial cells for the seeding of vascular grafts [50].

Seeding Techniques
The traditional approach to placing cells on a scaffold for TEVG creation is static
cell seeding, in which the patient’s cells are pipetted directly onto a graft before being
given several hours to attach. There are a number of recognized shortcomings of the
static seeding method, including lower final seeding efficiency and inter-operator
variability. A number of alternatives have been proposed, including dynamic, magnetic,
vacuum, electrostatic, and centrifugal seeding [51]. The leading option at this point
seems to be vacuum seeding in a specially designed chamber, which is both more
standardized and more effective in that it allows for rapid, operator-independent, and selfcontained cell seeding [52].

Patient Selection
Although vascular tissue engineering holds the promise of many great advances
over existing treatments for vascular disease, it remains a new field in only the infancy of
its clinical application and so caution is warranted. Any clinical trial is by necessity a
slow process and with pediatric patients that are so sick to begin with, research subject
selection must proceed with care [53, 54].
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Imaging Advances
Along with recent developments in vascular tissue engineering technology, many
great strides have been made in the field of imaging in order to monitor TEVG
development and function in vivo. These include the use of ultra-small particles of iron
oxide to enable direct tracking of cells in vivo in order to study TEVG development in
animal models using MRI and other imaging modalities [55, 56]. In the future these
tissue engineering and imaging technologies will hopefully be translated to the clinic in
parallel to aid in the evaluation of vascular grafts in human subjects.

Improving Clinical Outcomes
The findings of Shinoka’s clinical trial in Japan are encouraging but also point to
some of the possible issues and challenges with the use of vascular grafts in the pediatric
population. Translational research groups can now return to animal models in the lab to
improve TEVG outcomes [35]. Further investigation will identify critical mediators
controlling the formation of stenosis in TEVG. An important goal is to use these
discoveries to guide rational design of second-generation TEVG: first by targeting critical
mediators of stenosis, the primary cause of TEVG failure, in order to design grafts with
improved long-term patency; and second, by elucidating molecular mechanisms that
control vascular neotissue formation in order to create cytokine or drug-eluting TEVG,
which would not require cell seeding. The development of a TEVG that does not require
cell seeding would improve the off-the-shelf availability of TEVG and dramatically
increase its clinical utility.
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Molecular Mechanisms of TEVG Stenosis
As previously described, Breuer and Shinoka have developed a method for
fabricating TEVG scaffolds on a much smaller scale, enabling implantation in a murine
model using microsurgical technique [28]. We have used the mouse model to
investigate the cellular and molecular mechanisms underlying neovessel formation and
the development of TEVG stenosis, the primary mode of graft failure in the Japanese
clinical trial. In our mouse model, stenosis develops over a two-week time course [57].
Since seeded bone marrow mononuclear cells tend to prevent stenosis, we use an
unseeded TEVG model as an approach to studying graft stenosis [57].
In our previous studies we demonstrated that the seeded cells are critical to the
process of neovessel formation and function to inhibit the formation of TEVG stenosis.
However we also noted that the seeded cells rapidly disappear from the TEVG suggesting
that they exert their effect via a paracrine mechanism [31]. Additionally we showed that
vascular neotissue arises from ingrowth of cells arising from the neighboring blood
vessel, thus demonstrating that neovessel formation is a regenerative process [34]. Based
on our discovery that neovessels arise from ingrowth of cells from the neighboring blood
vessel wall and the finding that smooth muscle cells accumulate in occluded grafts, we
hypothesized that endothelial-mesenchymal transition may play an important role in the
process of neovessel formation and the development of TEVG stenosis.
It is well known that development of neointima underlies a number of common
diseases including post-angioplasty and vascular graft restenosis, hypertension, and
atherosclerosis [58, 59]. Despite decades of investigations, the origin of neointima still
remains controversial with studies variously pointing to the role of medial smooth muscle
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cell (SMC) proliferation [60], vessel wall inflammation [61] and adventitial angiogenesis
[62]. Endothelial-mesenchymal transition (EMT) is a complex process by which ECs
lose their attachments, differentiate and migrate. This phenomenon occurs normally
during human development in organogenesis in the heart [63, 64]. EMT has recently
been shown to participate in several pathological processes including cardiac fibrosis
[65], fibrodysplasia ossificans [66] and portal hypertension [67]. Basement membrane
damage in the kidney has been shown to cause epithelial cells to release cytokines that
initiate EMT [68]. Fibrosis in a heart disease model was mediated by EMT and reduced
by blocking the pathway [65]. EMT is thought to be driven by TGF-B in a Smaddependent and independent manner [67, 69]. However, factors initiating EMT and
suppressing its occurrence even in the normal vasculature remain poorly understood and
are areas of active investigation [70].
Transforming growth factor B (TGF-B) is a multifunctional signaling molecule
that regulates cell proliferation, differentiation, adhesion, migration, and apoptosis
through signal transduction at two types of activin receptor-like kinases (ALKs) via Smad
and MAPK pathways [71]. TGF-B exerts its effects by binding to and complexing type 1
and type 2 serine/threonine kinase transmembrane receptors. A ligand-induced
heteromeric receptor complex results and the constitutively active type 2 receptor is then
able to phosphorylate the type 1 receptor (TGFBR1). Once the type 1 receptor is
activated, the Smad signaling molecules are recruited, form complexes, and translocate
into the nucleus, where they are then able to regulate the transcription of specific gene
targets [71]. Conflicting roles in angiogenesis and pathogenesis have been assigned to
TGF-B as an inhibitor of proliferation and migration of ECs and enhancer of extracellular
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matrix (ECM) accumulation and differentiation of mesenchymal cells into pericytes and
smooth muscle cells [72]. A variety of studies have shown that TGF-B signaling plays
essential roles in normal vessel development and physiology and that aberrant TGF-B
signaling is key to a number of vascular disorders [64, 73].
Fibroblast growth factors (FGF) have also recently emerged as key molecular
regulators of normal vascular biology [74]. Circulating and tissue-resident FGFs signal
via cognate tyrosine kinase receptors that require an intracellular adaptor FRS2 for the
initiation of most intracellular signals, including a critical MAPK pathway [75].
Experimental evidence using various in vitro models points to a role for FGFs in
inhibition of TGF-B signaling [76]. Thus, FGF2 downregulates TGFBR1 expression and
attenuates endothelial cell response to TGF-B [77] and antagonizes TGF-B-mediated
smooth muscle actin expression [78]. In addition, FGF can revert TGF-B-induced EMT
in epithelial cells via the MAPK pathway [79]. These observations suggest that loss of
endothelial FGF signaling may lead to the upregulation of the TGF-B pathway and
promotion of EMT.
Reports that EMT is driven by TGF-B suggest that blocking TGFBR1 signaling
might inhibit EMT in our tissue engineered vascular graft and therefore improve TEVG
patency [80]. We hypothesized that ECs in our TEVG undergo EMT driven by TGF-B to
contribute to stenosis. To explore this process in our mouse model of TEVG formation,
we used two endothelial cell lineage-tracing models to show that EMT occurs during
neovessel formation. We also determined that TGF-B signaling is increased in occluded
grafts. Based on this result we treated mice systemically with a small molecule TGFBR1
inhibitor (SB-431542) and showed improved patency. Finally, we used a novel system
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for local delivery of this TGFBR1 inhibitor to prevent stenosis without cell seeding while
maintaining normal neovessel formation.
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Statement of Purpose
The development of an autologous tissue engineered vascular graft holds great
promise for improving outcomes in congenital heart surgery. Currently used synthetic
grafts are a significant source of morbidity and mortality, suggesting the need for
alternative therapies. The first clinical trial evaluating the use of TEVG created by
seeding autologous bone marrow-derived mononuclear cells onto biodegradable scaffolds
showed that this approach is both safe and effective but that the primary mode of TEVG
failure is graft stenosis. Preliminary data demonstrate that endothelial-mesenchymal
transition driven by TGF-B, known to play a critical role in other vascular processes
similar to TEVG vascular neotissue formation such as neointimal hyperplasia, may be
involved in TEVG stenosis. The goal of this research project is to investigate the TGF-Bmediated mechanisms of vascular neotissue formation with a focus on mechanisms
affecting formation of graft stenosis.

Hypotheses
1)

TEVG stenosis results from TGF-B mediated endothelial-mesenchymal transition

2)

Modulation of EMT can be used to reduce the incidence of stenosis in our TEVG

Specific Aims
1)

To determine the relative contribution of EMT to TEVG stenosis

2)

To modulate the pathways inhibiting or promoting EMT with the ultimate goal of

reducing TEVG stenosis
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Methods
(All methods performed by Daniel R. Duncan unless stated otherwise)

Scaffold Fabrication
TEVG scaffolds were constructed from a nonwoven polyglycolic acid (PGA) mesh
(Concordia Fibers) and a co-polymer sealant solution of poly-L-lactide and –εcaprolactone (P(CL/LA)) as previously described [28]. Briefly, tubular scaffolds were
formed by compressing a 6.0 mm x 6.0 mm sheet of nonwoven P(CL/LA) felt between a
21-gauge stainless steel rod (to maintain the inner lumen) and a cylindrical cored-out
polypropylene rod. The polymeric scaffolds were coated with a 50:50 copolymer sealant
solution of poly– -caprolactone-l-lactide (263,800 Da; Absorbable Polymers
International, Birmingham, Ala) dissolved at 5% wt/vol in dioxane. Scaffolds were snap
frozen at −20°C for 30 minutes and then lyophilized overnight to remove solvent. SB431542-eluting PGA-P(CL/LA) scaffolds were fabricated by substituting a 5% w/v
P(CL/LA) containing 3 mg/ml SB-431542. Scaffolds were coated with fibrin and
thrombin and sterilized at room temperature under UV light prior to implantation.
Scaffolds used for in vitro drug release studies were not coated with fibrin or thrombin.

Bone Marrow Seeding of TEVGs
For scaffold seeding studies, bone marrow was collected from the femurs of syngeneic
C57BL/6 mice. Following purification of the mononuclear cell component using
Histopaque-1086 (Sigma) centrifugation, one million mononuclear cells were manually
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pipetted onto the scaffold. The seeded scaffold was incubated in RPMI 1640 Medium
(Gibco) overnight prior to implantation as previously described [28].

Generation of mice and embryos

(Performed by Pei-Yu Chen, PhD)

Tie2-Cre (gift from W. C. Sessa, Yale University School of Medicine) transgenic mice or
Cdh5-CreERT2 (gift from R. H. Adams, Cancer Research UK London Institute)
transgenic mice were crossed with R26R-lacZ [B6,129-Gt(ROSA)26Sortm1Sho/J] (JAX
SN:003309) or mT/mG [B6,129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J] (JAX
SN:007676) mice to generate endothelial cell-specific reporter mice. For embryo
analysis, timed matings were set up and the morning of the vaginal plug was considered
as embryonic day 0.5 (E0.5). Embryos were genotyped by PCR analysis of the yolk sacs.
PCR genotyping was performed by using the following primers: Rosa26 (5'GCGAAGAGTTTGTCCTCAACC-3', 5'-AAAGTCGCTCTGAGTTGTTAT-3' and 5'GGAGCGGGAGAAATGGATATG-3'), Tie2-Cre (5'GCGGTCTGGCAGTAAAAACTATC-3', 5'-GTGAAACAGCATTGCTGTCACTT-3',
5'-CTAGGCCACAGAATTGAAAGATCT-3', and 5'GTAGGTGGAAATTCTAGCATCATC C-3').

Tamoxifen administration

(Performed by Pei-Yu Chen, PhD)

Tamoxifen was used to induce Cre expression in the Cdh5-CreERT2 mouse line. 100 mg
tamoxifen (Sigma) was dissolved in 5 ml corn oil (20 mg/ml final concentration). The
solution was mixed at 37°C overnight. Pups were pipette fed with 0.05 mg/g tamoxifen
solution every other day for 8 times total.
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TEVG Implantation

(Surgical implantations performed primarily by Tai Yi, MD with

assistance from Narutoshi Hibino, MD PhD and Yuji Naito, MD; pre-operative care,
anesthesia, and post-operative care performed by Daniel R. Duncan)
All animal experiments were done in accordance with Yale institutional guidelines for the
use and care of animals, and the institutional review board approved the experimental
procedures described. TEVG scaffolds were inserted into the infrarenal inferior vena cava
(IVC) of 8-10 week old, female mice as previously described [28]. Briefly, female
C57BL/6 mice (6-8 weeks old, Jackson Laboratory, Bar Harbor, ME) were anesthetized
with intraperitoneal injections of ketamine (100 mg/kg) (Hospira, Inc, Lake Forest, Ill)
and xylazine (10 mg/kg) (Ben Venue Laboratories, Bedford, Ohio). After preparation and
sterilization of the abdomen with betadine and alcohol, a midline laparotomy incision
was made. The IVC was identified and exposed using an 18× dissecting microscope
(Zeiss, Thornwood, NY), and the abdominal cavity bathed in heparinized solution (250
U/mL) (Baxter, Deerfield, Ill). Control of the IVC was obtained just inferior to the renal
veins and superior to the iliac veins. TEVG scaffolds fabricated as above were implanted
as infrarenal IVC interposition grafts via microsurgical technique. All anastomoses were
preformed in an end-to-end technique using 10-0 monofilament nylon sutures (Sharpoint
Lab Sutures, Calgary, Alberta, Canada) in interrupted stitches. Adequate hemostasis was
achieved before closing the abdominal cavity. Graft recipients were recovered from
surgery on warmed pads and evaluated for evidence of hind limb ischemia, paralysis, or
acute graft thrombosis before being returned to their cages. All mice were maintained
postoperatively without the use of any anticoagulation or antiplatelet therapy.
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Tissue preparation and histology
Explanted grafts were pressure fixed in 10% formalin overnight and then embedded in
paraffin or glycolmethacrylate using previously published methods [31]. Sections were
stained with H&E or Gomori Trichrome by Yale Orthopedic Histology. For cryosection
preparation, tissues were isolated from anesthetized mice, fixed 2 hr in 4%
paraformaldehyde (PFA) at room temperature, cryoprotected in 30% sucrose overnight at
4°C and embedded in OCT (Tissue-Tek). Frozen tissue was then cut into 10-um-thick
sections.

TEVG analysis
Graft luminal diameters were measured using Image J software. Stenosis was defined as
greater than 50% decrease in luminal diameter. Critical stenosis was defined as 80%
narrowing of the luminal diameter. Graft occlusion was defined as 100% narrowing of
the luminal diameter. TGF-B positive cell area was measured using ImageJ software.
Two separate sections of each explant were counterstained with hematoxalin and imaged
at 400X magnification. The number of nuclei was then counted in five regions of each
section and averaged. LacZ/SMA colocalized cells were quantified in the same manner
using double immunofluorescent staining imaged under 60X confocal magnification
using a Leica SP5 confocal microscope.

Whole mount X-gal staining
The expression of LacZ in scaffolds was detected by X-gal (β-glactosidase) staining
using a beta-gal staining kit according to the manufacturer’s instructions (MILLIPORE).
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Following X-gal staining, the scaffolds were refixed, dehydrated, embedded in paraffin,
and sectioned at 6 μm. The paraffin sections were then countered with eosin before being
photographed.

Immunohistochemistry
Samples were fixed in 4% paraformaldehyde overnight, washed in 70% ethanol,
embedded in paraffin and sectioned (6 um). Slides were dewaxed in xylene, antigen
retrieval was performed by boiling for 20 min in citrate buffer, rehydrated and blocked in
5% normal goat serum in PBS-T for 30 min at room temperature. Primary antibodies
included: β-galactosidase (Ab9361, Abcam), Calponin, clone hCP (C-2687, Sigma),
CD31 (Ab28364-100, Abcam), smooth muscle α-actin (M0851, Dako), vWF (Dako),
TGF-B (Ab53169, Abcam), VE-cadherin (C-19, Santa Cruz). Antibody binding was
detected using appropriate biotinylated secondary antibodies, followed by binding of
streptavidin-HRP and color development with 3,3-diaminobenzidine (Vector). Nuclei
were then counterstained with hematoxylin. For immunofluorescence detection, a goatanti-rabbit IgG-Alexa Fluor 568 (Invitrogen) or a goat-anti-mouse IgG-Alexa Fluor 488
(Invitrogen) was used with subsequent 4',6-diamidino-2-phenylindole nuclear
counterstaining. Immunofluorescence was detected using a Leica SP5 confocal
microscope. For each experiment, negative controls were used where sections were
treated without primary antibody and stained with secondary antibodies only.
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Quantitative Real Time PCR (qRT-PCR)

(SYBR Green PCR performed by Pei-Yu

Chen, PhD)
Explanted tissue grafts were frozen in OCT (Tissue-Tek) and each sectioned into forty
10um sections using Cryocut 1800 (Leica). Excess OCT was removed by centrifugation
in water. RNA was then isolated using RNeasy plus Mini Kit (Qiagen) and converted to
cDNA using iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time PCR was
performed using Bio-Rad CFX94 (Bio-Rad) by mixing equal amount of cDNAs, iQ
SYBR Green Supermix (Bio-Rad) and gene specific primers. For TGFBR1, the
following primer sequences were used: 5’-TCCCAACTACAGGACCTTTTTCA -3’ and
5’-GCAGTGGTAAACCTGATCCAGA -3’. For Vimentin, the following primer
sequences were used: 5’-CGGCTGCGAGAGAAATTGC-3’ and 5’CCACTTTCCGTTCAAGGTCAAG-3’. For mouse TGF-B we used the TaqMan
detection system (Mm00441726_m1; Applied Biosystems) and followed the
manufacturer's recommendations. All reactions were done in a 25 ul reaction volume in
duplicate. Data were normalized to an endogenous control b-actin. Values are expressed
as fold change in comparison to control.

sFGFR1-IIIc adenovirus administration

(Tail vein injections performed with

assistance from Nancy Kirkiles-Smith, PhD)
sFGFR1-IIIc adenovirus was administered as previously described [74] at a dose of
5x1010 viral particles per mouse 1 week prior to TEVG implantation by tail vein injection.
Control mice were given equivalent volumes of sterile PBS. Serum level of sFGFR1-IIIc
was measured by a Human IgG Subclass Profile kit (Invitrogen).
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Mouse treatment with systemic SB431542
Mice treated systemically with TGFBR1 kinase inhibitor were treated with SB431542
hydrate (Sigma) in DMSO given by intraperitoneal injection twice a day from postoperative day 0 to post-operative day 14 at a dose of 10 mg/kg. Control mice were treated
with equivalent volumes of sterile DMSO.

Microparticle synthesis and characterization

(Performed by Joseph Patterson,

YSM II with guidance from Tarek Fahmy, PhD)
SB-431542 (Sigma-Aldrich Cat. No. S4317) was encapsulated in avidin-coated PLGA
microparticles using a modified oil/water single emulsion technique [81]. Briefly, 5 mg
of drug and 100 mg PGLA (50/50 monomer ratio, Durect Corp. Cat. No. B0610-2)
dissolved in 2 ml chloroform and 200 ul DMSO were added dropwise with vortexing to 4
mL of aqueous surfactant solution containing 2.5 mg/mL polyvinyl alcohol (PVA)
(Sigma-Aldrich Cat. No. 363138) and 2.5 mg/mL avidin−palmitate bioconjugate to create
an emulsion containing microsized droplets of polymer/solvent, encapsulated SB-431542
and surfactant. Solvent was removed by magnetic stirring at 20C; hardened
microparticles were then washed 3× in DI water and lyophilized for long-term storage at 20C. Control avidin-coated PLGA microparticles were synthesized as above without SB431542. Microparticle size and morphology were analyzed via scanning electron
microscopy (SEM). Samples were sputter-coated with gold under vacuum in an argon
atmosphere using a sputter current of 40 mA (Dynavac Mini Coater, Dynavac, USA).
SEM analysis was carried out with a Philips XL30 SEM using a LaB electron gun with
an accelerating voltage of 10 kV.
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Preparation of adhesive peptide tether

(Performed by Joseph Patterson, YSM II

with guidance from Tarek Fahmy, PhD)
Poly-L-lysine-LC-LC-biotin (pLLB) was synthesized and used as an adhesive peptide
tether to enhance loading of PGA-P(CL/LA) scaffolds with avidin-coated microparticles.
1.66 mg EZ-Link sulfo NHS-LC-LC-biotin was reacted with 10 ml of a 0.1 mg/ml
solution of poly-L-lysine (MW 70,000-150,000, Sigma-Aldritch Cat. No. P4707 ) in 1x
PBS for 2 hours at 4C, dialyzed in 1x PBS for 72 hours, and stored at 4C.

Loading of TEVG scaffolds with SB-431542-eluting microparticles (Performed by Joseph
Patterson, YSM II with guidance from Tarek Fahmy, PhD)
Nonspecific adsorption of avidin-coated PLGA microparticles to PGA-P(CL/LA)
scaffolds not treated with pLLB was titrated by incubating scaffolds trimmed to 5 mm in
axial length with 1 ml of 1, 5, or 10 mg/ml of microparticles in 1x PBS for 10, 30 or 60
minutes. Particle-loaded TEVG scaffolds were immediately snap frozen in liquid
nitrogen and lyophilized for 6 hours before imaging. Scaffold loading efficiency was
determined with ImageJ software (Image Processing and Analysis in Java, National
Institute of Health, Bethesda, MD) from three SEM images per scaffold cross section,
inner surface, and outer surface by calculating the mean surface density of particles. The
effect of scaffold pretreatment with pLLB on scaffold loading efficiency was assessed
from particle loading density as above after PGA-P(CL/LA) scaffolds were incubated
with 1 ml of 0.01, 0.1 or 1 mg/ml pLLB for 60 minutes on a rotary shaker, washed 3
times with dH2O, incubated with 1 ml 5 mg/ml avidin-coated PLGA microparticles on a
rotary shaker, washed 3 times with dH2O, snap frozen in liquid nitrogen, lyophilized for
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6 hours, and imaged by SEM. For in vitro and in vivo studies, PGA-P(CL/LA) scaffolds
were incubated with pLLB for 30 minutes at 20C on a rotary shaker, washed 3 times with
dH2O, incubated with 5 mg/ml empty or SB-431542-eluting avidin-coated PLGA
microparticles for 30 minutes on a rotary shaker, washed 3 times with dH2O, snap frozen
in liquid nitrogen, and lyophilized for 6 hours before storage in a dessicator.

Characterization of SB-431542 release from microparticles and scaffolds (Performed by
Joseph Patterson, YSM II)
Total encapsulation was approximated as the amount of SB-431542 released over a 14day period. Percent encapsulation efficiency was calculated as total encapsulation divided
by maximum theoretical encapsulation. 5 mg of avidin-coated PLGA microparticles
containing SB-431542, PGA-P(CL/LA) scaffolds trimmed to 5 mm axial length and
treated with pLLB and SB-431542-eluting microparticles as above, and SB-431542eluting PGA-P(CL/LA) scaffolds trimmed to 5 mm axial length were incubated with 400
μl 1x PBS in 2 ml microcentrifuge tubes in triplicate on a rotary shaker at 37C. Samples
were removed at time points of 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 168, 240, and 336
hours and centrifuged at 13200 RPM for 10 ten minutes. 300 μl of supernatant was drawn
and replaced with 300 μl 1x PBS. Concentration of SB-431542 in supernatant diluted
with 600 μl 1x PB was determined by spectrophotometry at 320 nm in a quartz cuvette.

Bioactivity of encapsulated SB-431542by p-SMAD immunoblot
Cleary, MD)

(Performed by Muriel

35
SB-431542 was released into 1 ml 1x PBS from 10 mg avidin-coated PLGA
microparticles and one untrimmed SB-431542-eluting PGA-P(CL/LA) scaffold in 2 ml
microcentrifuge tubes on a rotary shaker at 37C. At 48 hours, samples were centrifuged at
13200 RPM for 10 ten minutes, supernatants were collected and analyzed by
spectrophotometry at 320 nm. SB-431542 concentrations were adjusted to 10 μM by
dilution with 1x PBS. 3T3 human fibroblasts were plated at 500,000/well on a 6-well
plate and stimulated at confluence with 700 ul 10 μM SB-431542 in PBS eluted from
particles or scaffolds, a stock solution of 10 or 1 μM SB-431542 containing <1% DMSO,
1 or 1x PBS. After 30 minutes at 37C, cells were washed with warm PBS and stimulated
with 200 ul 2 ng/ml recombinant human TGF-β1 (BD Biosciences, Cat. No. 354039) for
1 hour at 37C. Cells were lysed with ice cold RIPA lysis buffer containing phosphatase
and proteinase inhibitors (PhosSTOP and cOmplete mini, Roche Applied Science, Cat.
No. 04906845001 and 04693116001). Cell lysates were collected in 200 μl ice cold 1x
PBS by scraping, vortexed for 15 seconds, agitated on a rotary shaker at 4C for 30
minutes, and centrifuged at 12000 RPM for 15 minutes at 4C. Supernatant protein
concentrations were determined by DC protein assay (Bio-Rad Life Science, Hercules,
CA) and protein samples were separated by gel electrophoresis with a 12%
polyacrylamide gel. Samples were transferred to a PVDF membrane, blocked with 5%
milk, and probed with primary rabbit monoclonal antibody against phosphorylated
SMAD-2 (ser426/ser428, Cell Signaling Technology, Cat . No. 3010) and secondary goat
anti-rabbit IgG (Cell Signaling Technology, Cat. No. 7074). The gel was stripped in
stripping buffer (50 ml 62.5 mM Tris-HCl, 2% SDS, 100 mM β-mercaptoethanol) for 40
minutes at 50C with agitation and reprobed with anti-SMAD2/3 as a loading control. The
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proteins were visualized with ECL exposure on HyBlot x-ray film and analyzed for band
density.

Statistical analysis
Data are the mean ± standard deviation. Statistical comparisons between groups were
performed by the one-way analysis of variance followed by the Student’s t-test. Patency
rates were compared using the Fisher’s Exact Test. P values less than 0.05 were
considered significant.
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Results
EMT occurs during neovessel formation
We performed endothelial cell lineage-tracing studies in order to map the fate of the
endothelial cells in our TEVG as they transitioned from endothelial cells to mesenchymal
cells while maintaining expression of LacZ. Implantation of our graft into a Tie2-Cre
transgenic mouse model (n=9) demonstrated co-localization of LacZ with SMA and
Calponin, mesenchymal cell markers, suggesting the occurrence of EMT (Figure 4a).
We validated these studies using a Cdh5-CreERT2 transgenic mouse model (n=7) and
again demonstrated co-localization of LacZ with SMA and Calponin, confirming our
previous results (Figure 4c). In both models, LacZ-positive cells are found throughout
the entire neointima and have lost expression of the endothelial cell marker CD31.

EMT contributes to occlusion in TEVG
We quantified the degree of EMT in our TEVG by performing confocal analysis and
cellular quantification of TEVG samples double stained for LacZ and SMA. In a
comparison of patent to occluded grafts we found co-localization of both markers in 3851% of smooth muscle cells (Figure 4b, d) suggesting that EMT significantly contributes
to occlusion in our TEVG.
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Figure 4: Cell fate mapping demonstrating EMT using two transgenic
models

Figure 4:
Cell fate mapping demonstrating EMT using two transgenic models.
A. Tie2 model with first row images of model development showing specificity of
lineage tracing using LacZ in aorta and second row showing lineage tracing images in
occluded TEVG in Tie2 mice. (Scale bar: 12 μm). B. Quantification demonstrating that
EMT significantly contributes to TEVG stenosis in the Tie2 model. (*p<0.05). C. Cdh5
model with first row images of model development showing specificity of lineage tracing
using LacZ in aorta and second row showing lineage tracing images in occluded TEVG
in Cdh5 mice. D. Quantification demonstrating that EMT significantly contributes to
TEVG stenosis in the Cdh5 model, replicating the results shown with the Tie2 model.
(**p<0.01).
Expression of TGF-B and TGFBR1 are associated with EMT
At 2 weeks, patent TEVGs have an organized neovessel structure with an intima
consisting of vWF positive endothelial cells and a media consisting of SMA positive
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smooth muscle cells. In contrast, occluded grafts show SMA positive smooth muscle cell
accumulation (Figure 5a). Both immunohistochemical staining and qRT-PCR
demonstrate increased expression of TGF-B in unseeded grafts when compared to grafts
seeded with bone marrow mononuclear cells, a procedure previously shown to
dramatically improve graft patency (Figure 5b, c). In an analysis of our unseeded grafts,
qRT-PCR showed increased TGF-B, TGFBR1, and vimentin expression in occluded
grafts at 2 weeks when compared to 1 week samples, the time course over which stenosis
has been shown to take place in our model (Figure 5d).

Figure 5: TGF-B signaling plays a role in TEVG stenosis

Figure 5:
TGF-B signaling plays a role in TEVG stenosis. A. Smooth muscle
cells are implicated in stenosis. B. Higher TGF-B expression in occluded grafts by IHC.
C. Higher TGF-B expression in unseeded grafts compared to seeded grafts by qRT-PCR.
D. Higher expression of TGF-B and TGFBR1 at 2 weeks in unseeded TEVG by qRTPCR. (***p<0.001).
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Regulation of TGFBR1 by FGF Signaling in TEVGs
To determine if transcriptional regulation of TGFBR1 by FGF signaling plays a role in
TEVG stenosis, we systemically expressed a soluble FGF trap (Ad-sFGFR1-IIIc) that has
been previously demonstrated to virtually shutdown FGF signaling [74] one week before
implantation of TEVG seeded with bone marrow mononuclear cells, a procedure known
to dramatically improve the graft patency (Figure 6a, upper panel). Two weeks after graft
implantation, there were significantly higher TEVG neointima burden and stenosis rate in
mice injected with Ad-sFGFR1-IIIc (n=15) compared to saline-injected control mice
(n=15) (Figure 6b, c). Serum was analyzed for sFGFR1-IIIc by sandwich ELISA to
confirm FGF trap expression in treated mice (Figure 6a, lower panel).

Figure 6: FGF blockade using a viral trap to upregulate TGF-B
signaling increases stenosis

Figure 6:
FGF blockade using a viral trap to upregulate TGF-B signaling
increases stenosis. A. Schematic representation of the seeded TEVG implantation
schedule for mice with tail vein injection of sFGFR1-IIIc virus or saline. Serum was
analyzed for sFGFR1-IIIc by sandwich ELISA. Data shown represents mean ± SD from 2
wells per group. B. Qualitative IHC demonstrating patent control and stenosed virustreated neovessel histology. C. TEVG stenosis rate in control and sFGFR1-IIIc treated
mice. (*p<0.05 compared to control).
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Inhibition of TGFBR1 inhibits stenosis but does not block neovessel formation
We treated mice with the TGFBR1 inhibitor SB-431542 at 10 mg/kg twice daily by
intraperitoneal administration for 2 weeks following implantation of our TEVG (n=16).
Matched control mice received intraperitoneal injection of sterile DMSO (n=25). Results
of these studies showed that TGFBR1 inhibitor treatment increases TEVG luminal
diameter and graft patency at 2 weeks in unseeded grafts (Figure 7a). Drug treatment
also allows for proper neotissue creation with an organized CD31-positive endothelial
cell layer lining an SMA-positive smooth-muscle cell layer in contrast to the typical
untreated control graft that occludes as a result of accumulation of SMA-positive smooth
muscle cells (Figure 7b).

Figure 7: Systemic SB431542 treatment reduces TEVG stenosis by
blocking EMT

Figure 7:
Systemic SB431542 treatment reduces TEVG stenosis by blocking
EMT. A. SB431542 experiment with quantitative analysis of patency and luminal
diameter. B. Qualitative IHC demonstrating normal neovessel histology. C. Results of
experiment combining Tie2 lineage tracing model with SB treatment to demonstrate that
drug treatment significantly reduces the occurrence of EMT in occluded TEVG.
(*p<0.05; **p<0.01; ***p<0.001).
TGFBR1 inhibition blocks EMT
In order to unravel the mechanism by which SB431542 treatment prevents TEVG
stenosis, we treated mice from the Tie2 lineage-tracing model (n=10) with TGFBR1
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inhibitor drug and then performed confocal analysis and cellular quantification of TEVG
samples double stained for LacZ and SMA. Results of these studies showed that drug
treatment improves patency by significantly reducing the occurrence of EMT as
demonstrated by a significant reduction in LacZ-positive smooth muscle cells in occluded
grafts in drug treated mice (Figure 7c).

Local delivery of TGFBR1 inhibitor inhibits stenosis without cell seeding and
maintains normal neovessel formation
We developed a novel microparticle system for local delivery of the TGFB R1 inhibitor
SB431542 in order to minimize possible effects of systemic delivery (Figure 8a). We
characterized this system to show that there is steady release of the drug across the full 2week time course during which the grafts are implanted (Figure 8b), and showed that the
released drug maintains its biologic activity (Figure 8c). We also developed a simpler
local drug delivery system by which the TGFBR1 inhibitor was added to the solvent used
to make the grafts and again demonstrated a favorable release profile and continued
biologic activity of the released drug (Figure 8b, c). We then implanted both types of
drug-eluting grafts in our mouse model (n=10 for drug in microparticles, n=24 for drug in
solvent) and compared their patency to control grafts with empty microparticles (n=10) or
control grafts (n=25). Results of these studies showed that local drug delivery
significantly increases patency at 2 weeks in unseeded grafts and also enables neotissue
creation (Figure 8d, e).
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Figure 8: Local delivery of SB431542 reduces TEVG stenosis

Figure 8:
Local delivery of SB431542 reduces TEVG stenosis. A. SEM of
particles seeded on inner lumen of TEVG. B. Absolute and fractional release of SB431542 from (▪) tethered PLGA microparticles and (Δ) PCLA phase of a PGA-PCLA
TEVG scaffold. C. Western for Smad2 and pSmad2 demonstrating bioactivity of
SB431542 released from both types of scaffold. E. Quantitative analysis of patency and
luminal diameter. (**p<0.01; NS = not significant) F. Qualitative IHC demonstrating
normal neovessel histology.
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Discussion
We have adopted a bench to the bedside and back approach to developing
vascular tissue engineering technology. Our previous clinical studies have demonstrated
the feasibility of using this technology in humans while also highlighting its unique
advantages and in particular the growth capacity of our tissue engineered vascular graft
[25]. These studies have also informed us that the primary graft related complication in
humans is stenosis and thus have served to focus our ongoing laboratory investigations
[22]. The development and use of the mouse IVC interposition model that recapitulates
neovessel formation in a manner similar to that observed in large animal studies and
human studies has provided us with a powerful tool for investigating neovessel formation
[28, 31]. These laboratory studies provide us with clinically relevant information that we
can apply to the rational design of improved second generation TEVGs [82]. This goal is
predicated on improving our understanding of the cellular and molecular mechanisms
underlying neovessel formation and the development of TEVG stenosis.
The results of the present study suggest that endothelial-mesenchymal transition
under the control of TGF-B is a significant mediator of stenosis in our tissue engineered
graft model and that modulation of this pathway might be useful in the development of
improved tissue engineered vascular grafts for clinical use. The current study is the first
to show endothelial-mesenchymal transition plays a role in TEVG stenosis. This was
determined using two distinct and robust endothelial cell lineage-tracing models [66, 83].
For the first model, Tie2-Cre is constitutively active during embryonic development
while in the second model the Cdh5-Cre construct was induced by tamoxifen on the
second postnatal day. In both cases approximately half of neointimal smooth muscle cells
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inside the TEVG were marked with LacZ, suggesting endothelial cell origin. Therefore,
both models showed that stenosed and occluded grafts have a significantly higher
percentage of cells that have transitioned from endothelial cells to smooth muscle cells as
shown by loss of endothelial markers and gain of smooth muscle markers.
Endothelial-mesenchymal transition is a complex process that has been shown to
have important roles in normal development and in other models of disease, including
tumor metastasis and cardiac and renal fibrosis [63, 84]. EMT results from a complicated
signaling process that is now better understood to be driven by TGF-B [84]. TGF-B has
been discussed as playing an important role in restenosis in variety of other vascular
models [85]. We confirmed that TGF-B is involved in stenosis in our TEVG mouse
model by using both immunohistochemical analysis and qRT-PCR to show increased
TGF-B and TGFBR1 expression at 2 weeks compared to 1 week in unseeded grafts and
in a comparison between seeded and unseeded grafts. Both of these are clinically
significant results since 2 weeks has been shown to be the key time point for the
development of stenosis in our mouse model and graft seeding is a procedure known to
increase patency in our graft [57].
Based on the finding that EMT and TGF-B play a role in graft stenosis along with
the understanding that FGF signaling inhibits TGF-B signaling, we used a soluble FGFtrap adenovirus to block FGF signaling in our mice [74]. In this way we were able to at
least indirectly increase TGF-B signaling to determine the effects of this change on graft
patency. As expected, this resulted in increased stenosis in our TEVG, providing more
evidence that TGF-B signaling is intimately involved in graft stenosis.
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Next, based on the results of our lineage-tracing models along with the wellknown link between EMT and TGF-B signaling, we were able to rationally select a small
molecule inhibitor of TGFBR1 and test its effect on stenosis in our TEVG. SB-431542 is
a selective small molecule inhibitor of ALK5 that antagonizes TGF-B receptor type 1 and
has been shown to block TGF-B mediated fibrosis [86-88]. We started with a systemic
twice-daily treatment approach for mice that were implanted with our grafts. Results of
these experiments revealed that the TGFBR1 inhibitor increased patency in our graft
while allowing for normal neotissue formation with organized smooth muscle and
endothelial cell layers. Combining this drug treatment with the power of our EC lineagetracing model, we were importantly able to show that treatment with this drug
specifically inhibits EMT in our graft. Therefore, we can conclude that inhibition of
TGFBR1 signaling in our TEVG decreases stenosis specifically by decreasing the
occurrence of EMT.
In order to further refine our approach to drug-based modulation of EMT and
reduce the possibility of systemic side effects, we developed two local delivery methods
for the TGFBR1 inhibitor. The first involved dissolving the drug in dioxane, the solvent
used in the standard preparation of our TEVG, and thus incorporating it into the graft as
the PCLA polymer is applied to the PGA fibers in graft production. In this case, the drug
was released off the graft as the TEVG itself degraded by hydrolysis. The second
approach involved developing a novel microparticle system in which the same drug was
encapsulated in PLGA microparticles and bound in place by an avidin-biotin molecular
tether. In this setting, the drug was eluted into the circulation as the microparticles
degraded over time. Both approaches enabled local delivery of the TGFBR1 inhibitor at
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greatly lowered doses and when grafts made with these drug delivery systems were
implanted in mice we again saw a significant improvement in stenosis at two weeks along
with normal neotissue formation. Interestingly, the drug worked to prevent stenosis with
each of these delivery methods even though both the rate of release and total amount
released differed between the two approaches. In using both a simple approach and a
more sophisticated method, we have importantly developed two different platforms that
could be adapted for the use of a variety of other drugs that work at varying time points to
prevent stenosis.
TGF-B is a complex signaling molecule that has been shown to play a variety of
roles throughout development, physiology, and disease. Other groups have shown that a
possible effect of TGF-B is to inhibit MCP-1 expression [89, 90] and that macrophages
also have other mechanisms for counteracting the effects of TGF-B [91]. Previous
studies in our lab have shown the importance of the cytokine MCP-1 in coordinating the
process of neotissue formation, likely by attracting the appropriate monocyte populations
to the graft that direct or participate in tissue regeneration [31]. An interesting
formulation of the results of this study is that perhaps by blocking the effects of TGF-B in
our grafts we are allowing MCP-1 and the monocytes and macrophages it attracts to
properly coordinate neotissue formation.
In our previous studies we have shown in the formation of TEVG that the degree
of macrophage infiltration into the TEVG is correlated with the degree of development of
TEVG stenosis is an immune mediated phenomena [57]. We previously evaluated
macrophage depletion using clodronate liposomes as a potential strategy for inhibiting
the development of TEVG stenosis. Using this strategy we were able to inhibit stenosis;
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however, we also noted inhibition of neotissue formation, including absence of
endothelial cell and smooth muscle cell formation on the luminal surface of the scaffold
in addition to a paucity of ECM production. Based on these studies we concluded that
macrophage infiltration into the TEVG scaffold was essential for vascular neotissue
formation [57]. In contradistinction, inhibition of EMT by blocking TGFBR1 inhibited
the formation of TEVG stenosis without blocking vascular neotissue formation and
neovessel formation, a significant accomplishment in our path to developing a better
tissue engineered vascular graft.
While administration of SB431542 was well tolerated in our study as
demonstrated by no alteration in the surgical morbidity and mortality rates and
maintenance of normal growth of our animals during the course of our study, potential
systemic side effects are clearly of concern [92]. In order to minimize the systemic
toxicity of TGFBR1 inhibition we investigated the use of local controlled release as a
strategy for minimizing systemic toxicity. Our data suggests this is a viable strategy,
resulting in a decreased incidence of stenosis and excellent neovessel formation as
evidenced by normal neovessel histology. We used both a straightforward and a more
sophisticated approach and in so doing also developed two novel platform technologies
for the local delivery of drug in our TEVG. These would enable the use of a variety of
small molecules to guide and improve neovessel development in vivo.

Limitations of the Present Study
There are several limitations of the present study, which must be taken into
account when considering the results. While our study has only been performed in a
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tissue-engineered model, it likely has applications to neointima formation and stenosis in
other models. Intravascular stenosis following TEVG implantation is typical of other
vascular injury restenosis models [93] but this needs to be verified in other settings such
as intraluminal balloon injury or carotid artery ligation. Similarly, the current study only
included experiments with our mouse model of a tissue engineered vascular graft.
Further work with large animal models as our lab has pursued in the past would need to
be performed to get a better sense of whether these results can be applied to the clinical
trial in humans [32]. With regards to our transgenic mouse model experiments, we nicely
showed that drug treatment reduces EMT using the Tie2 endothelial cell lineage-tracing
model but this will also need to be verified using our Cdh5 lineage-tracing model.
Similarly, local drug delivery will need to be used in the lineage-tracing setting to show
that it has the same effect to block EMT. Additionally, in our use of the FGF trap virus
we unfortunately present only indirect evidence that increased TGF-B signaling leads to
increased stenosis in our TEVG. An important follow-up experiment will require some
mode of treatment with TGF-B to show that this results in an increase in stenosis,
whether by viral expression of TGF-B or systemic treatment with exogenous TGF-B.
Additionally, we primarily focused on the endothelial cell markers CD31 and vWF and
the smooth muscle cell markers SMA and Calponin in analyzing the occurrence of EMT
in our TEVG model. Further investigation would involve confirming these results with
EMT quantification using additional cell phenotype markers. Finally, in regard to both
methods of local drug delivery, the release profiles were performed in vitro, and so it
must be taken into account that the results are not necessarily representative of what
occurs in vivo once the grafts are implanted in the mice.
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Next Steps
Although the current study enables significant advances in our understanding of
mechanisms of TEVG stenosis, many unanswered questions remain to be explored to
further clarify the exact role of EMT in this process and how best to modulate this
pathway to create a better TEVG for clinical use.
It has been shown that the EMT pathway diverges down two different signaling
modalities based on whether it involves signaling through the Smads [84, 85]. Our
approach has essentially focused on the Smad-dependent arm of this pathway by using
the TGFBR1 inhibitor SB-431542, but an important next step would be to further unravel
the EMT pathway as it occurs in our TEVG model and determine the Smad-dependence
of the EMT pathway in TEVG stenosis.
An additional area of future investigation would involve determining where the
endothelial cells that participate in EMT in our graft originate. The traditional view of
this is that the endothelial cells migrate from the vessel wall, from cell populations in
either the intima or the adventitia. However, more recent studies suggest the possibility
of a circulating endothelial cell progenitor origin for these cells [94]. More sophisticated
cell tracking experiments will be necessary to unravel these origins.
Most of our analysis has been focused at two weeks post-implantation since we
have previously shown that this is the key time point for establishment of TEVG patency
or stenosis [57]. However, we need to more deeply understand the exact timing of
stenosis and establish a finer timeline for the occurrence of EMT in TEVGs to know if
treatment is necessary and exactly when it would be most beneficial. This would involve
looking at earlier time-points to determine the role of EMT in the acute phase of
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neotissue formation and following mice for longer than 2 weeks with and without drug
treatment to make sure the improvement in patency can be sustained.
Intriguingly, there are a variety of other possible inhibitors of the TGF-B
signaling pathway including the ACE-inhibitor Losartan and several other drugs already
in clinical use [95-99]. A better understanding of which components of the EMT
pathway are involved in the formation of stenosis will enable us to continue to take a
rational approach to selecting and screening drugs for their efficacy in preventing graft
stenosis. Exploring other possible small molecule inhibitors of EMT might help us to
find more safe and effective drugs for use in our TEVG.
An additional important area of investigation will be to use transgenic mouse
models to better define the role of TGFBR1 and other components of the TGF-B signal
transduction pathway in TEVG stenosis. In the long term we hope to use an endothelial
cell-specific TGFBR1 conditional knockout mouse [64] to show that defective TGFBR1
signaling leads to decreased graft stenosis by means of a reduction in EMT. Such a result
would provide more robust support for our current findings and enable a variety of other
experiments to further unravel the mechanisms of stenosis in our TEVG.

Conclusions
The importance of EMT to neointima formation is only now beginning to be
appreciated. Early studies have demonstrated the presence of mesenchymal-type cells in
human restenotic lesions [93] but the significance and the origin of these cells have not
been well defined. The current study ties together several lines of evidence including the
importance of endothelial cell proliferation in neointima formation [62], the role of TGF-
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B signaling in EMT [62], and the ability of FGF to affect TGF-B-induced EMT [79]. The
inhibition of neointima formation by interference with this signaling pathway may open
new therapeutic venues in a variety of clinical settings.
In this study we demonstrated that the process of endothelial-mesenchymal
transition is involved in the formation of neotissue stenosis and occlusion in tissue
engineered vascular grafts. Furthermore, we demonstrated that modulation of EMT by
means of blockade of the TGF-B signaling pathway is a viable strategy for inhibiting the
formation of TEVG stenosis and that this can also be done equally well by local drug
delivery. There is certainly a complex route to stenosis in TEVGs and EMT is not
necessarily the only or even the dominant pathway in this process but the results of this
study suggest that EMT is at least one component of this phenomenon in our TEVG
model.
Perhaps the most interesting finding of our study is that local delivery of TGFBR1
inhibitor could be used in place of cell seeding. The ability to perform cell-free tissue
engineering has significant implications which would dramatically improve the clinical
utility of this technology by enabling off the shelf availability without the need for cell
harvesting, cell isolation, cell seeding, or incubation in vitro, all of which increase the
potential complications associated with the use of this technology in humans. In
addition, the notion that we can create a man-made device that induces organized tissue
regeneration holds great promise for other regenerative medicine applications.
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